Cell and gene therapies are considered highly innovative but also challenging approaches in modern cardiology. While early hopes for adult stem cells from bone marrow or skeletal muscle were largely disappointed, pluripotent stem cells and gene editing methods are now coming into focus. Results from preclinical studies are encouraging, but have not (yet) been confirmed to the same extent in clinical trials. The main problems are immunological issues, arrhythmia risks, costs, lack of reproducibility and, in some cases, ethical concerns. Future developments, including advanced gene editing without double-strand breaks (base/prime editing) or targeted epigenetic modulation, promise to further develop the potential of regenerative medicine in the field of cardiology.
Autoren
- Tanja Schliebe
Publikation
- CARDIOVASC
Related Topics
You May Also Like
- Plea for sex-specific neurology
Migraine in men: underdiagnosed, underestimated, under-researched
- Prurigo nodularis
Retrospective analyses of large data sets from everyday practice
- Public Health
Outpatient care in Switzerland: situation report
- Practice Management
Improved quality of care aims for satisfied patients
- Chemsex - MSM, sex, chrystal meth & co.
Medical and psychosocial perspectives
- Bladder cancer
Tuberculosis vaccination reduces recurrences
- Oral JAK-i in atopic dermatitis
Benefits and risks: What does the current data say?
- Sleep-wake disorders in pneumology practice